Stella Pharma Corp. (4888)
Market Closed
12 Aug, 06:00
JPX JPX Primary ¥
325. 00
+7
+2.2013%
¥
8.88B Market Cap
- P/E Ratio
- Div Yield
281,100 Volume
- Eps
¥ 318
Previous Close Want to track 4888 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
4888 closed today higher at ¥325, an increase of 2.2013% from yesterday's close, completing a monthly increase of 4.5016% or ¥14. Over the past 12 months, 4888 stock gained 59.3137%.
4888 is not paying dividends to its shareholders.
The last earnings report, released on May 12, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
Stella Pharma Corp. (4888) FAQ
What is the stock price today?
The current price is ¥325.00.
On which exchange is it traded?
Stella Pharma Corp. is listed on JPX.
What is its stock symbol?
The ticker symbol is 4888.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 8.88B.
Has Stella Pharma Corp. ever had a stock split?
No, there has never been a stock split.
Stella Pharma Corp. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Tomoyuki Asano CEO | JPX Exchange | JP3399680002 ISIN |
| Japan Country | 43 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Stella Pharma Corporation is a dynamic entity in the pharmaceutical industry, focusing on the advancement of boron neutron capture therapy (BNCT) for cancer treatment. Since its establishment in 2007 and being headquartered in Osaka, Japan, the company dedicates itself to the research, development, manufacturing, and distribution of pharmaceuticals. With a vigorous approach towards innovation, Stella Pharma aims to provide groundbreaking solutions for various cancers by leveraging the potential of BNCT technology.
Products and Services
- SPM-011: This is Stella Pharma Corporation’s lead product, a boron-containing drug designed specifically for use in Boron Neutron Capture Therapy (BNCT). The drug aims to offer a new hope in the treatment of several types of cancers, including:
- Head and Neck Cancer: Targeting this area, SPM-011 is being developed to offer an alternative for patients with tumors in these locations, providing a focused approach that aims to minimize damage to surrounding healthy tissues.
- Recurrent Malignant Glioma and Meningioma: These aggressive brain tumors pose significant treatment challenges, and SPM-011 represents a potential breakthrough in treatment methodologies, offering targeted therapy with the hope of improving survival rates and quality of life for patients.
- Malignant Melanoma and Angiosarcoma: For these skin and soft tissue cancers, SPM-011 provides a promising treatment avenue, potentially improving outcomes for patients with these often rapidly spreading and difficult-to-treat conditions.
Contact Information
Address: ORIX Kouraibashi Building
Phone: 81 6 4707 1516
Website: https://www.stella-pharma.co.jp
